mmpL3 Resolved · high auto-curated

H37Rv Rv0206c · MTBC0 mtbc0_000220 · 944 aa · 244836–247670 MTBC0 (-) · RefSeq NP_214720.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)transmembrane transport protein MmpL3
MTBC0 PGAP re-annotationtrehalose monomycolate RND transporter MmpL3
Revised (this work)Trehalose monomycolate RND transporter MmpL3. Pfam: MMPL (PF03176.22).
Functional category (TubercuList)cell wall and cell processes

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 225 publications

225 TB publications mention this gene. 225 publications discuss this gene. Queried separately, 197 records carry a M. tuberculosis context and 68 a non-TB mycobacterial context (species named in the 40-record verified sample: M. smegmatis (26), M. abscessus (12), M. leprae (2), M. marinum (2)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 225: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Structure, assembly, and mechanism of the MmpL family of transporters. doi:10.1128/mmbr.00139-26 2026
Proton Transfer Mechanisms in the MmpL3 Transporter of Mycobacterium tuberculosis Studied by Computer Simulations. doi:10.1021/acsbiomedchemau.5c00274 2026
Design of benzofuro [3,2-d] pyrimidine-based MmpL3 inhibitors as potential anti-tuberculosis agents using integrated in silico approaches. doi:10.1007/s40203-026-00646-z 2026
Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor-binding mechanisms. doi:10.1107/S2059798326003050 2026
A bioluminescence-based chemical screen identifies a bactericidal naphthalen-1-ylmethanamine scaffold targeting MmpL3 in Mycobacterium abscessus. doi:10.1016/j.celrep.2026.117311 2026
232 records returned by the alias sweep (a separate sweep from the 225 above; both are shown, neither is exhaustive)

Searched as: Rv0206c, mmpL3, Mb0212c, ML2620c, MMAR_0446, MSMEG_0250, MAB_4508 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
A TmaT-AftD interaction is required for the CmpL4 mycomembrane biogenesis pathway in Corynebacterium glutamicum. doi:10.64898/2026.07.31.741767 bioRxiv 2026
Synthesis, computational and in vitro anti-tubercular activity studies of thiadiazole-linked pyridazinone derivatives. doi:10.1016/j.bmcl.2026.130761 Bioorg Med Chem Lett 2026
Polar growth factor PgfA regulates polar peptidoglycan synthesis as well as mycolate synthesis in Mycobacterium smegmatis. doi:10.1128/jb.00269-26 J Bacteriol 2026
Structure, assembly, and mechanism of the MmpL family of transporters. doi:10.1128/mmbr.00139-26 Microbiol Mol Biol Rev 2026
Proton Transfer Mechanisms in the MmpL3 Transporter of Mycobacterium tuberculosis Studied by Computer Simulations. doi:10.1021/acsbiomedchemau.5c00274 names it ACS Bio Med Chem Au 2026
Design of benzofuro [3,2-d] pyrimidine-based MmpL3 inhibitors as potential anti-tuberculosis agents using integrated in silico approaches. doi:10.1007/s40203-026-00646-z names it In Silico Pharmacol 2026
Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor-binding mechanisms. doi:10.1107/S2059798326003050 names it Acta Crystallogr D Struct Biol 2026
A bioluminescence-based chemical screen identifies a bactericidal naphthalen-1-ylmethanamine scaffold targeting MmpL3 in Mycobacterium abscessus. doi:10.1016/j.celrep.2026.117311 names it Cell Rep 2026
Identification of potential MenT3 inhibitors for Mycobacterium tuberculosis using the generative artificial intelligence and SilicoXplore platform. doi:10.1038/s41598-026-49174-y Sci Rep 2026
Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors. doi:10.1016/j.ejmech.2026.118841 names it Eur J Med Chem 2026
Combined computational and classical medicinal chemistry procedure to disclose novel pyrrole-based compounds as potential antituberculosis agents. doi:10.1007/s10822-026-00794-6 J Comput Aided Mol Des 2026
Polar growth factor PgfA regulates polar peptidoglycan synthesis as well as mycolate synthesis in Mycobacterium smegmatis. doi:10.64898/2026.03.27.714885 bioRxiv 2026
Polynuclear Silver(I)-Quinoxaline Complex: Comprehensive Structural Characterization, Antimycobacterial Properties and DNA/BSA Binding Study. doi:10.3390/pharmaceutics18020169 Pharmaceutics 2026
Integrating computational and biological approaches for the discovery of putative MmpL3 inhibitors against Mycobacterium tuberculosis. doi:10.1007/s11030-026-11478-6 names it Mol Divers 2026
Molecular modelling assisted identification of novel Benzoxazole derivatives as hit molecules targeting Mycobacterial Membrane Protein Large 3 (MmpL3). doi:10.1016/j.compbiomed.2026.111521 names it Comput Biol Med 2026
Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems. doi:10.3390/pharmaceutics18010060 Pharmaceutics 2026
Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection. doi:10.1128/aac.01105-25 Antimicrob Agents Chemother 2026
Defining the Mechanism of Action and Resistance of New Mycobacterium abscessus MmpL3 Inhibitors. doi:10.1021/acschembio.5c00709 names it ACS Chem Biol 2026
Contribution of Proteins to Membrane and Cell Wall Structures in Mycobacterium tuberculosis. doi:10.1007/978-3-031-96883-9_4 Adv Exp Med Biol 2026
Cryo-electron microscopy (Cryo-EM) structural determination of the MmpL family of transporters. doi:10.1016/bs.mie.2025.10.002 Methods Enzymol 2025
Reconstitution and functional characterization of MmpL3, an essential transporter from Mycobacterium tuberculosis. doi:10.1016/bs.mie.2025.08.025 names it Methods Enzymol 2025
A bioluminescence-based chemical screen identifies a bactericidal naphthalene scaffold targeting MmpL3 in Mycobacterium abscessus. doi:10.1101/2025.10.26.684512 names it bioRxiv 2025
Optimization of pyrrole-2-carboxamide to develop a potent antituberculosis agent with improved physicochemical property and druggability. doi:10.1016/j.bioorg.2025.109016 Bioorg Chem 2025
Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis. doi:10.1128/aac.00980-25 names it Antimicrob Agents Chemother 2025
Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis. doi:10.1128/aac.00368-25 names it Antimicrob Agents Chemother 2025
Common Biological Properties of Mycobacterium tuberculosis MmpL3 Inhibitors. doi:10.1021/acsinfecdis.5c00394 names it ACS Infect Dis 2025
Mechanistic evaluation of Clerodendrum serratum anti-biofilm potency against Mycobacterium species. doi:10.1016/j.micpath.2025.107985 Microb Pathog 2025
Scaffold Hopping Strategy toward New 4‑Aminoquinazolines Active Against Extracellular and Intracellular. doi:10.1021/acsmedchemlett.5c00276 ACS Med Chem Lett 2025
Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis. doi:10.1101/2025.06.26.661674 names it bioRxiv 2025
Review of Recent Advances in Thiazolidin-4-One Derivatives as Promising Antitubercular Agents (2021-Present). doi:10.3390/molecules30102201 Molecules 2025
Investigating the unbinding mechanisms and kinetics of MmpL3 inhibitors: A computational study. doi:10.1002/pro.70163 names it Protein Sci 2025
Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly. doi:10.1039/d5sc02565f Chem Sci 2025
Exploring spirocyclic isoquinoline-piperidine compounds in tuberculosis therapy: ADMET profiling, docking, DFT, MD simulations, and MMGBSA analysis. doi:10.1016/j.compbiolchem.2025.108447 Comput Biol Chem 2025
Genetic and Cheminformatic Characterization of Mycobacterium tuberculosis Inhibitors Discovered in the Molecular Libraries Small Molecule Repository. doi:10.1021/acsinfecdis.4c00936 ACS Infect Dis 2025
Mycobacterium tuberculosis CrgA Forms a Dimeric Structure with Its Transmembrane Domain Sandwiched between Cytoplasmic and Periplasmic β-Sheets, Enabling Multiple Interactions with Other Divisome Proteins. doi:10.1021/jacs.4c17168 J Am Chem Soc 2025
New pyrazole-based derivatives targeting MmpL3 transporter in Mycobacterium tuberculosis: design, synthesis, biological evaluation and molecular docking studies. doi:10.1007/s11030-025-11152-3 names it Mol Divers 2025
High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia. doi:10.3201/eid3103.241488 Emerg Infect Dis 2025
Developing novel indoles as antitubercular agents and simulated annealing-based analysis of their binding with MmpL3. doi:10.1080/17568919.2024.2444872 names it Future Med Chem 2025
Mycobacterium tuberculosis CrgA Forms a Dimeric Structure with Its Transmembrane Domain Sandwiched between Cytoplasmic and Periplasmic β-Sheets, Enabling Multiple Interactions with Other Divisome Proteins. doi:10.1101/2024.12.05.627054 bioRxiv 2025
Fluorescence-based CRISPR interference system for controlled genetic repression and live single-cell imaging in mycobacteria. doi:10.1002/1873-3468.15071 FEBS Lett 2025
Cryo-EM structure of the Mycobacterium smegmatis MmpL5-AcpM complex. doi:10.1128/mbio.03035-24 mBio 2024
Structures of the mycobacterial MmpL4 and MmpL5 transporters provide insights into their role in siderophore export and iron acquisition. doi:10.1371/journal.pbio.3002874 PLoS Biol 2024
Deciphering the possible role of MmpL7 efflux pump in SQ109 resistance in Mycobacterium tuberculosis. doi:10.1186/s12941-024-00746-8 Ann Clin Microbiol Antimicrob 2024
An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis. doi:10.1128/aac.01037-24 Antimicrob Agents Chemother 2024
MmpL3, Wag31, and PlrA are involved in coordinating polar growth with peptidoglycan metabolism and nutrient availability. doi:10.1128/jb.00204-24 names it J Bacteriol 2024
Design, synthesis, biological evaluation study of spirocyclic POM analogues as novel MmpL3 anti-tubercular agent. doi:10.1016/j.bioorg.2024.107823 names it Bioorg Chem 2024
Inhibitor binding and disruption of coupled motions in MmpL3 protein: Unraveling the mechanism of trehalose monomycolate transport. doi:10.1002/pro.5166 names it Protein Sci 2024
The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective. doi:10.1111/cbdd.14612 Chem Biol Drug Des 2024
Integrating computational and experimental approaches in discovery and validation of MmpL3 pore domain inhibitors for specific labelling of Mycobacterium tuberculosis. doi:10.1016/j.ijbiomac.2024.135212 names it Int J Biol Macromol 2024
Allosteric coupling of substrate binding and proton translocation in MmpL3 transporter from Mycobacterium tuberculosis. doi:10.1128/mbio.02183-24 names it mBio 2024
The mycobacterium lipid transporter MmpL3 is dimeric in detergent solution, SMALPs and reconstituted nanodiscs. doi:10.1039/d4cb00110a names it RSC Chem Biol 2024
Structural modeling and characterization of the Mycobacterium tuberculosis MmpL3 C-terminal domain. doi:10.1002/1873-3468.15007 names it FEBS Lett 2024
CRISPR Interference-Mediated Silencing of the mmpL3 Gene in Mycobacterium smegmatis and Its Impact on Antimicrobial Susceptibility. doi:10.3390/antibiotics13060483 names it Antibiotics (Basel) 2024
Antibiotic resistance in Mycobacterium tuberculosis alters tolerance to cell wall-targeting inhibitors. doi:10.1093/jacamr/dlae086 JAC Antimicrob Resist 2024
MmpL3, Wag31 and PlrA are involved in coordinating polar growth with peptidoglycan metabolism and nutrient availability. doi:10.1101/2024.04.29.591792 names it bioRxiv 2024
Novel Inhibitors to MmpL3 Transporter of Mycobacterium tuberculosis by Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulations. doi:10.1021/acsomega.3c08401 names it ACS Omega 2024
Synthesis, biological evaluation and molecular docking study of pyrimidine linked thiazolidinedione derivatives as potential antimicrobial and antitubercular agents. doi:10.1016/j.bmcl.2024.129707 Bioorg Med Chem Lett 2024
S288T mutation altering MmpL3 periplasmic domain channel and H-bond network: a novel dual drug resistance mechanism. doi:10.1007/s00894-023-05814-y names it J Mol Model 2024
The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection. doi:10.1128/spectrum.03677-23 names it Microbiol Spectr 2024
Synthesis, antitubercular profile and molecular docking studies of quinazolinone-based pyridine derivatives against drug-resistant tuberculosis. doi:10.1080/07391102.2023.2217928 J Biomol Struct Dyn 2024
Cryo-EM structure of the trehalose monomycolate transporter, MmpL3, reconstituted into peptidiscs. doi:10.1016/j.crstbi.2023.100109 names it Curr Res Struct Biol 2023
Silencing essential gene expression in Mycobacterium abscessus during infection. doi:10.1128/spectrum.02836-23 Microbiol Spectr 2023
Inhibition Mechanism of Anti-TB Drug SQ109: Allosteric Inhibition of TMM Translocation of Mycobacterium Tuberculosis MmpL3 Transporter. doi:10.1021/acs.jcim.3c00616 names it J Chem Inf Model 2023
Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents. doi:10.1016/j.ejmech.2023.115633 names it Eur J Med Chem 2023
In vitro bioevaluation and docking study of dihydrosphingosine and ethambutol analogues against sensitive and multi-drug resistant Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2023.115579 Eur J Med Chem 2023
Inoculum-dependent bactericidal activity of a Mycobacterium tuberculosis MmpL3 inhibitor. doi:10.1099/mic.0.001345 names it Microbiology (Reading) 2023
New therapeutic strategies for Mycobacterium abscessus pulmonary diseases - untapping the mycolic acid pathway. doi:10.1080/14787210.2023.2224563 Expert Rev Anti Infect Ther 2023
Discovery and biological evaluation of an adamantyl-amide derivative with likely MmpL3 inhibitory activity. doi:10.1016/j.tube.2023.102350 names it Tuberculosis (Edinb) 2023
Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections. doi:10.1080/17460441.2023.2218082 Expert Opin Drug Discov 2023
Study of SQ109 analogs binding to mycobacterium MmpL3 transporter using MD simulations and alchemical relative binding free energy calculations. doi:10.1007/s10822-023-00504-6 names it J Comput Aided Mol Des 2023
In vivo imaging of MmpL transporters reveals distinct subcellular locations for export of mycolic acids and non-essential trehalose polyphleates in the mycobacterial outer membrane. doi:10.1038/s41598-023-34315-4 Sci Rep 2023
Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents. doi:10.1016/j.ejmech.2023.115351 names it Eur J Med Chem 2023
Gene recoding by synonymous mutations creates promiscuous intragenic transcription initiation in mycobacteria. doi:10.1101/2023.03.17.532606 bioRxiv 2023
Insights into substrate transport and water permeation in the mycobacterial transporter MmpL3. doi:10.1016/j.bpj.2023.03.018 names it Biophys J 2023
Inoculum-dependent bactericidal activity of a Mycobacterium tuberculosis MmpL3 inhibitor. doi:10.1101/2023.02.22.529622 names it bioRxiv 2023
Molecular Mechanisms of MmpL3 Function and Inhibition. doi:10.1089/mdr.2021.0424 names it Microb Drug Resist 2023
Targeting mycobacterial membranes and membrane proteins: Progress and limitations. doi:10.1016/j.bmc.2023.117212 Bioorg Med Chem 2023
Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against Mycobacterium abscessus and Malaria Parasites. doi:10.1021/acsinfecdis.2c00537 ACS Infect Dis 2023
Pharmacophore based virtual screening & molecular docking approach for identification of mycobacterial membrane protein large 3 (MmpL3) inhibitors. doi:10.1080/07391102.2022.2159876 names it J Biomol Struct Dyn 2023
Structural Determinants of Indole-2-carboxamides: Identification of Lead Acetamides with Pan Antimycobacterial Activity. doi:10.1021/acs.jmedchem.2c00352 J Med Chem 2023
Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3. doi:10.1016/j.tube.2022.102288 names it Tuberculosis (Edinb) 2023
Isoxazole carboxylic acid methyl ester-based urea and thiourea derivatives as promising antitubercular agents. doi:10.1007/s11030-022-10543-0 Mol Divers 2023
Diversity and novel mutations in membrane transporters of Mycobacterium tuberculosis. doi:10.1093/bfgp/elac018 Brief Funct Genomics 2023
Computational design of MmpL3 inhibitors for tuberculosis therapy. doi:10.1007/s11030-022-10436-2 names it Mol Divers 2023
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development. doi:10.1186/s43556-022-00106-y Mol Biomed 2022
Deployment of iron uptake machineries as targets against drug resistant strains of mycobacterium tuberculosis. doi:10.4103/ijp.IJP_667_20 Indian J Pharmacol 2022
MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. doi:10.3390/biomedicines10112793 names it Biomedicines 2022
An essential periplasmic protein coordinates lipid trafficking and is required for asymmetric polar growth in mycobacteria. doi:10.7554/eLife.80395 Elife 2022
A Hydrazine-Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3. doi:10.3390/molecules27207130 names it Molecules 2022
Molecular insights into Mmpl3 leads to the development of novel indole-2-carboxamides as antitubercular agents. doi:10.1039/d1me00122a names it Mol Syst Des Eng 2022
Fragment-Based Drug Discovery against Mycobacteria: The Success and Challenges. doi:10.3390/ijms231810669 Int J Mol Sci 2022
Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening. doi:10.1038/s41598-022-19192-7 Sci Rep 2022
Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents. doi:10.1016/j.crphar.2022.100119 Curr Res Pharmacol Drug Discov 2022
Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3. doi:10.1016/j.str.2022.07.009 names it Structure 2022
Molecular Modelling and Atomistic Insights into the Binding Mechanism of MmpL3 Mtb. doi:10.1002/cbdv.202200160 names it Chem Biodivers 2022
The driving force for mycolic acid export by mycobacterial MmpL3 is proton translocation. doi:10.1073/pnas.2211130119 names it Proc Natl Acad Sci U S A 2022
Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis. doi:10.1021/acs.jmedchem.2c00718 J Med Chem 2022
The 1, 2-ethylenediamine SQ109 protects against tuberculosis by promoting M1 macrophage polarization through the p38 MAPK pathway. doi:10.1038/s42003-022-03693-2 Commun Biol 2022
Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis. doi:10.3390/molecules27144446 Molecules 2022
Proton transfer activity of the reconstituted Mycobacterium tuberculosis MmpL3 is modulated by substrate mimics and inhibitors. doi:10.1073/pnas.2113963119 names it Proc Natl Acad Sci U S A 2022
A holistic molecular modelling approach to design novel indole-2-carboxamide derivatives as potential inhibitors of MmpL3. doi:10.1080/1062936X.2022.2096691 names it SAR QSAR Environ Res 2022
Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections. doi:10.1039/d1md00359c RSC Med Chem 2022
Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular Mycobacterium tuberculosis. doi:10.1128/spectrum.01161-22 Microbiol Spectr 2022
Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. doi:10.1016/j.ejmech.2022.114404 Eur J Med Chem 2022
Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment. doi:10.3390/pharmaceutics14030610 names it Pharmaceutics 2022
Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection. doi:10.1093/jac/dkab437 J Antimicrob Chemother 2022
MmpL3, the trehalose monomycolate transporter, is stable in solution in several detergents and can be reconstituted into peptidiscs. doi:10.1016/j.pep.2021.106014 names it Protein Expr Purif 2022
Mycobacterial membrane protein Large 3-like-family proteins in bacteria, protozoa, fungi, plants, and animals: A bioinformatics and structural investigation. doi:10.1002/prot.26273 Proteins 2022
Analysis of the oligomeric state of mycobacterial membrane protein large 3 and its interaction with SQ109 with native cell membrane nanoparticles system. doi:10.1016/j.bbamem.2021.183793 Biochim Biophys Acta Biomembr 2022
Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of Mycobacterium tuberculosis and paediatric brain tumour cells. doi:10.1039/d0ra10728j RSC Adv 2021
The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation. doi:10.1016/j.tcsw.2021.100068 names it Cell Surf 2021
The pipeline of new molecules and regimens against drug-resistant tuberculosis. doi:10.1016/j.jctube.2021.100285 J Clin Tuberc Other Mycobact Dis 2021
A road map to structure-resistance correlations on Mycobacterium tuberculosis MmpL3. doi:10.1016/j.str.2021.09.007 names it Structure 2021
The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism. doi:10.3390/ijms22168533 Int J Mol Sci 2021
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.1c00837 J Med Chem 2021
Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport. doi:10.1371/journal.pbio.3001370 names it PLoS Biol 2021
Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis. doi:10.1002/cmdc.202100359 names it ChemMedChem 2021
Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate. doi:10.1021/acsinfecdis.1c00259 ACS Infect Dis 2021
Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target. doi:10.1016/j.str.2021.06.013 names it Structure 2021
Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. doi:10.1128/AAC.00024-21 Antimicrob Agents Chemother 2021
Specifically Targeting Mtb Cell-Wall and TMM Transporter: The Development of MmpL3 Inhibitors. doi:10.2174/1389203722666210421105733 names it Curr Protein Pept Sci 2021
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. doi:10.1021/acsomega.0c05589 names it ACS Omega 2021
Trehalose Recycling Promotes Energy-Efficient Biosynthesis of the Mycobacterial Cell Envelope. doi:10.1128/mBio.02801-20 mBio 2021
Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies. doi:10.1021/acs.jmedchem.0c01727 J Med Chem 2021
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.0c00675 names it ACS Infect Dis 2021
Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis. doi:10.1016/j.bioorg.2020.104486 Bioorg Chem 2021
Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis. doi:10.3389/fcimb.2020.582416 Front Cell Infect Microbiol 2020
Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450. doi:10.3390/ijms21207683 Int J Mol Sci 2020
Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors. doi:10.1128/mSphere.00985-20 names it mSphere 2020
Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents. doi:10.1039/c9ra10663d RSC Adv 2020
Resistance against Membrane-Inserting MmpL3 Inhibitor through Upregulation of MmpL5 in Mycobacterium tuberculosis. doi:10.1128/AAC.01100-20 names it Antimicrob Agents Chemother 2020
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets. doi:10.2174/1568026620666200903163921 Curr Top Med Chem 2020
MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections. doi:10.3390/ijms21176202 names it Int J Mol Sci 2020
[New hopes for the treatment of persistent Mycobacterium abscessus infections?]. doi:10.1051/medsci/2020138 Med Sci (Paris) 2020
Targeting MmpL3 for anti-tuberculosis drug development. doi:10.1042/BST20190950 names it Biochem Soc Trans 2020
Structural Basis for the Inhibition of Mycobacterial MmpL3 by NITD-349 and SPIRO. doi:10.1016/j.jmb.2020.05.019 names it J Mol Biol 2020
The protein kinase PknB negatively regulates biosynthesis and trafficking of mycolic acids in mycobacteria. doi:10.1194/jlr.RA120000747 J Lipid Res 2020
MmpL3 inhibitors as antituberculosis drugs. doi:10.1016/j.ejmech.2020.112390 names it Eur J Med Chem 2020
Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition. doi:10.1021/acsinfecdis.0c00121 names it ACS Infect Dis 2020
Fast chemical force microscopy demonstrates that glycopeptidolipids define nanodomains of varying hydrophobicity on mycobacteria. doi:10.1039/c9nh00736a Nanoscale Horiz 2020
Photoactivatable Glycolipid Probes for Identifying Mycolate-Protein Interactions in Live Mycobacteria. doi:10.1021/jacs.0c01065 J Am Chem Soc 2020
Genome-wide identification of essential genes in Mycobacterium intracellulare by transposon sequencing - Implication for metabolic remodeling. doi:10.1038/s41598-020-62287-2 Sci Rep 2020
Structure-Based Design and Synthesis of Piperidinol-Containing Molecules as New Mycobacterium abscessus Inhibitors. doi:10.1002/open.202000042 ChemistryOpen 2020
Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus. doi:10.1128/AAC.02548-19 Antimicrob Agents Chemother 2020
Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus. doi:10.1021/acsinfecdis.9b00389 names it ACS Infect Dis 2020
The crystal structure of the mycobacterial trehalose monomycolate transport factor A, TtfA, reveals an atypical fold. doi:10.1002/prot.25863 Proteins 2020
The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes. doi:10.1007/s10123-019-00086-0 Int Microbiol 2020
Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem. doi:10.2174/1871526519666181205163810 Infect Disord Drug Targets 2020
Identification of novel scaffolds targeting Mycobacterium tuberculosis. doi:10.1007/s00109-019-01840-7 J Mol Med (Berl) 2019
Erratum: Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent. doi:10.3389/fmicb.2019.02298 Front Microbiol 2019
Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis. doi:10.1021/acsmedchemlett.9b00204 ACS Med Chem Lett 2019
A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3. doi:10.1074/jbc.RA119.010135 names it J Biol Chem 2019
Structural and functional evidence that lipoprotein LpqN supports cell envelope biogenesis in Mycobacterium tuberculosis. doi:10.1074/jbc.RA119.008781 J Biol Chem 2019
Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance. doi:10.1128/AAC.00547-19 names it Antimicrob Agents Chemother 2019
The MmpL3 interactome reveals a complex crosstalk between cell envelope biosynthesis and cell elongation and division in mycobacteria. doi:10.1038/s41598-019-47159-8 names it Sci Rep 2019
1H-Benzo[d]Imidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis. doi:10.1128/AAC.00441-19 names it Antimicrob Agents Chemother 2019
Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria. doi:10.1128/mBio.00850-19 names it mBio 2019
Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis. doi:10.1128/AAC.00629-19 names it Antimicrob Agents Chemother 2019
MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine. doi:10.1073/pnas.1901346116 names it Proc Natl Acad Sci U S A 2019
Advancing the Therapeutic Potential of Indoleamides for Tuberculosis. doi:10.1128/AAC.00343-19 Antimicrob Agents Chemother 2019
Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. doi:10.1021/acsinfecdis.9b00048 names it ACS Infect Dis 2019
Mycobacterial tuberculosis Enzyme Targets and their Inhibitors. doi:10.2174/1568026619666190219105722 Curr Top Med Chem 2019
Modification of drug-binding proteins associated with the efflux pump in MDR-MTB in course of evolution: an unraveled clue based on in silico approach. doi:10.1038/s41429-019-0146-3 J Antibiot (Tokyo) 2019
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. doi:10.1016/j.cell.2019.01.003 names it Cell 2019
Indole-2-Carboxamides Are Active against Mycobacterium abscessus in a Mouse Model of Acute Infection. doi:10.1128/AAC.02245-18 Antimicrob Agents Chemother 2019
Computational studies on N-phenyl pyrrole derivatives as MmpL3 inhibitors in Mycobacterium tuberculosis. doi:10.1016/j.compbiolchem.2018.11.007 names it Comput Biol Chem 2019
Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria. doi:10.1007/s10534-018-0157-8 names it Biometals 2019
Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption. doi:10.3389/fmicb.2018.02960 names it Front Microbiol 2018
Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent. doi:10.3389/fmicb.2018.02231 Front Microbiol 2018
Discovery of benzothiazole amides as potent antimycobacterial agents. doi:10.1016/j.bmcl.2018.08.026 Bioorg Med Chem Lett 2018
MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections. doi:10.3389/fmicb.2018.01547 names it Front Microbiol 2018
HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter. doi:10.1128/AAC.02459-17 names it Antimicrob Agents Chemother 2018
Use of Soluble Extracellular Regions of MmpL (SERoM) as Vaccines for Tuberculosis. doi:10.1038/s41598-018-23893-3 Sci Rep 2018
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. doi:10.1016/j.ejmech.2018.03.020 Eur J Med Chem 2018
Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets. doi:10.1038/s41598-018-22228-6 Sci Rep 2018
In vivo potent BM635 analogue with improved drug-like properties. doi:10.1016/j.ejmech.2017.12.075 Eur J Med Chem 2018
Variants of katG, inhA and nat genes are not associated with mutations in efflux pump genes (mmpL3 and mmpL7) in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. doi:10.1016/j.tube.2017.07.014 names it Tuberculosis (Edinb) 2017
Controlling Extra- and Intramacrophagic Mycobacterium abscessus by Targeting Mycolic Acid Transport. doi:10.3389/fcimb.2017.00388 Front Cell Infect Microbiol 2017
Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates. doi:10.3389/fmicb.2017.01539 Front Microbiol 2017
Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis. doi:10.1099/mic.0.000498 names it Microbiology (Reading) 2017
MmpL3 is the flippase for mycolic acids in mycobacteria. doi:10.1073/pnas.1700062114 names it Proc Natl Acad Sci U S A 2017
Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. doi:10.1021/acs.jmedchem.7b00582 J Med Chem 2017
Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity. doi:10.1016/j.bmc.2017.05.015 Bioorg Med Chem 2017
Improving the production of 22-hydroxy-23,24-bisnorchol-4-ene-3-one from sterols in Mycobacterium neoaurum by increasing cell permeability and modifying multiple genes. doi:10.1186/s12934-017-0705-x Microb Cell Fact 2017
The Mycobacterium tuberculosis MmpL11 Cell Wall Lipid Transporter Is Important for Biofilm Formation, Intracellular Growth, and Nonreplicating Persistence. doi:10.1128/IAI.00131-17 Infect Immun 2017
Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression. doi:10.1038/srep43495 names it Sci Rep 2017
Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro. doi:10.1128/AAC.02399-16 names it Antimicrob Agents Chemother 2017
Pharmaceutical salt of BM635 with improved bioavailability. doi:10.1016/j.ejps.2016.12.003 Eur J Pharm Sci 2017
Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.6b00095 names it ACS Infect Dis 2016
New and Old Hot Drug Targets in Tuberculosis. doi:10.2174/1389557516666160831164925 Curr Med Chem 2016
Diphenylether-Modified 1,2-Diamines with Improved Drug Properties for Development against Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.6b00052 ACS Infect Dis 2016
THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. doi:10.1038/nmicrobiol.2015.6 Nat Microbiol 2016
Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2016.07.028 Eur J Med Chem 2016
Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents. doi:10.1016/j.ejmech.2016.07.009 Eur J Med Chem 2016
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. doi:10.1128/AAC.00826-16 names it Antimicrob Agents Chemother 2016
Iron Acquisition Pathways as Targets for Antitubercular Drugs. doi:10.2174/0929867323666160607223747 Curr Med Chem 2016
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection. doi:10.1021/acs.jmedchem.6b00415 names it J Med Chem 2016
A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus. doi:10.1111/mmi.13406 Mol Microbiol 2016
MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. doi:10.2174/1389557516666160118105319 names it Mini Rev Med Chem 2016
Mechanistic insight into mycobacterial MmpL protein function. doi:10.1111/mmi.13306 Mol Microbiol 2016
Insights into the smooth-to-rough transitioning in Mycobacterium bolletii unravels a functional Tyr residue conserved in all mycobacterial MmpL family members. doi:10.1111/mmi.13283 Mol Microbiol 2016
Comparative metabolic profiling of mce1 operon mutant vs wild-type Mycobacterium tuberculosis strains. doi:10.1093/femspd/ftv066 Pathog Dis 2015
The Structure and Interactions of Periplasmic Domains of Crucial MmpL Membrane Proteins from Mycobacterium tuberculosis. doi:10.1016/j.chembiol.2015.07.013 Chem Biol 2015
3D-QSAR Selectivity Analysis of 1-Adamantyl-3-Heteroaryl Urea Analogs as Potent Inhibitors of Mycobacterium tuberculosis. doi:10.2174/1573409911666150803154114 Curr Comput Aided Drug Des 2015
Mycolic acids: deciphering and targeting the Achilles' heel of the tubercle bacillus. doi:10.1111/mmi.13101 Mol Microbiol 2015
Whole cell screen based identification of spiropiperidines with potent antitubercular properties. doi:10.1016/j.bmcl.2015.05.087 Bioorg Med Chem Lett 2015
Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development. doi:10.1016/j.bcp.2015.05.001 Biochem Pharmacol 2015
Acetylation of trehalose mycolates is required for efficient MmpL-mediated membrane transport in Corynebacterineae. doi:10.1021/cb5007689 ACS Chem Biol 2015
Design and synthesis of novel benzimidazole derivatives as anti-tuberculosis agents. Yao Xue Xue Bao 2014
Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. doi:10.1128/AAC.03229-14 names it Antimicrob Agents Chemother 2014
Trends in discovery of new drugs for tuberculosis therapy. doi:10.1038/ja.2014.109 J Antibiot (Tokyo) 2014
Mycobacterium tuberculosis proteins involved in mycolic acid synthesis and transport localize dynamically to the old growing pole and septum. doi:10.1371/journal.pone.0097148 PLoS One 2014
The Wag31 protein interacts with AccA3 and coordinates cell wall lipid permeability and lipophilic drug resistance in Mycobacterium smegmatis. doi:10.1016/j.bbrc.2014.04.116 Biochem Biophys Res Commun 2014
Multitarget drug discovery for tuberculosis and other infectious diseases. doi:10.1021/jm500131s J Med Chem 2014
MmpL3 a potential new target for development of novel anti-tuberculosis drugs. doi:10.1517/14728222.2014.859677 names it Expert Opin Ther Targets 2014
New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. doi:10.2174/1381612819666131118203641 Curr Pharm Des 2014
Indoleamides are active against drug-resistant Mycobacterium tuberculosis. doi:10.1038/ncomms3907 Nat Commun 2013
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. doi:10.1126/scitranslmed.3007355 Sci Transl Med 2013
Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? doi:10.1016/j.tube.2013.09.003 Tuberculosis (Edinb) 2013
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. doi:10.1371/journal.pone.0075245 PLoS One 2013
Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target. doi:10.4155/fmc.13.109 Future Med Chem 2013
The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11. doi:10.1074/jbc.M113.453076 names it J Biol Chem 2013
Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. doi:10.1371/journal.pone.0060933 names it PLoS One 2013
Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. doi:10.1016/j.bmc.2013.02.028 Bioorg Med Chem 2013
Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. doi:10.1371/journal.pone.0056980 names it PLoS One 2013
Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. doi:10.1021/cb300151m ACS Chem Biol 2012
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. doi:10.1016/j.bmc.2012.03.058 Bioorg Med Chem 2012
MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria. doi:10.1016/j.chembiol.2012.03.006 Chem Biol 2012
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. doi:10.1038/nchembio.794 Nat Chem Biol 2012
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. doi:10.1128/AAC.05708-11 names it Antimicrob Agents Chemother 2012
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. doi:10.1128/AAC.05270-11 names it Antimicrob Agents Chemother 2012
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. doi:10.1128/IAI.73.6.3492-3501.2005 Infect Immun 2005

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Intrinsic disorder (sequence + structure) partially disordered

Predicted disorder21% of residues (metapredict) · mean AlphaFold pLDDT 79.3
Disordered regions1 IDR(s), longest 194 aa [750-944]

carries a substantial disordered region (194/944 residues); disorder is a property, not a function

A property (biophysics), not a function. No LLPS/condensate claim is made from disorder alone. Verdict unchanged. Source: metapredict v3 (Emenecker/Holehouse) per-residue disorder + AlphaFold mean pLDDT (annotation_mtbc P16.13).

Genomic-neighbour overlap (structural caveat) antiparallel · 0 % of gene

NeighbourRv0205 (Rv0205, + strand)
Overlap4 bp, 0 % of this gene's length

antiparallel overlap: this gene may inherit essentiality/conservation signal from its neighbour through shared TA sites or promoter constraint, without any protein of its own being produced (cf. Rv2438A/nadE) Signals attributed to this gene (Tn-seq essentiality via shared TA sites, conservation via promoter constraint) should be cross-checked against the neighbour before being read as its own. P20.1, derived from GFF3 gene coordinates, 2026-08-03.

CRISPRi vulnerability

Vulnerability index -11.01 (95% CI -11.40 to -10.60). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Legacy record & comparison (Mycobrowser)

Mycobrowser functionUnknown. Thought to be involved in fatty acid transport.

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb0212c · 99.8% identity
M. leprae ML2620c · 75.4% identity
M. marinum MMAR_0446 · 74.6% identity
M. smegmatis MSMEG_0250 · 72.0% identity
M. orygis RJtmp_000221 · 99.7% identity
M. abscessus MAB_4508 · 62.6% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WJV5 SwissProt · reviewed · Evidence at protein level
UniProt nameTrehalose monomycolate exporter MmpL3
Curated functionTransports trehalose monomycolate (TMM) to the cell wall. Flips TMM across the inner membrane. Membrane potential is not required for this function. Transports probably phosphatidylethanolamine (PE) as well. Binds specifically both TMM and PE, but not trehalose dimycolate (TDM). Also binds diacylglycerol (DAG) and other phospholipids, including phosphatidylglycerol (PG), phosphatidylinositol (PI), and cardiolipin (CDL). Contributes to membrane potential, cell wall composition, antibiotic susceptibility and fitness (By similarity). Could also be part of a heme-iron acquisition system..; FUNCTIO.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category S Function unknown
Preferred namemmpL3
eggNOG descriptionlipid transport
Orthologous groupCOG2409
KEGG orthology K06994, K20466, K20470
Gene Ontology (33) GO:0005575, GO:0005576, GO:0005618, GO:0005623, GO:0005886, GO:0005887, GO:0006810, GO:0006869, GO:0008150, GO:0009273, GO:0009987, GO:0010876 +21 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.604 · relaxed/neutral
Polymorphic sites (≥ 0.1% of strains) 6 synonymous, 10 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Actinomycetia

M. canettii dN/dS (deep-divergence selection) 0.121 (low power) · 4 consensus substitution(s)
low power (4 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 52/53 (98%) · mean identity 73.3% · 4/4 closest MTBAP relatives
conserved across the genus (present in 52/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 8/13 non-Mycobacterium reference genomes (down to Actinomycetia) · mean identity 48.3%
detected across the class Actinomycetia (beyond Corynebacteriales) but not outside the phylum — an Actinobacteria-level ancient gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis) ESD — not strictly essential

The two screens differ on the SCOPE of what is required: Tn-seq says essential (domain-level only) (ESD), CRISPRi says essential.

These two screens are not in plain contradiction here, but they do not say the same thing either, and the difference matters for what may be written about this gene. Tn-seq (DeJesus 2017) places the requirement on a SUB-REGION of the ORF and explicitly declines to call the whole gene essential; CRISPRi (Bosch 2021) calls the gene essential under partial knockdown. Both point to an important gene; they disagree on the SCOPE of what is required. Locate the domain before concluding, and note that a stretch carrying no TA site is invisible to Himar1 Tn-seq — neither essential nor dispensable can be inferred there. Here the CRISPRi estimate is a confident one (its `certain` flag is set, vulnerability index -11.013), so the disagreement is a genuine methodological tension rather than a weak fit. Atlas-wide, 26 gene(s) fall in this exact stratum, out of 27 showing this direction of disagreement.

DeJesus 2017 callESD · essential domain
What the call meansessential domain: only a SUB-REGION of the ORF is essential; the gene as a whole is NOT essential. Locate the domain before concluding, and beware that a region devoid of TA sites is invisible to Himar1 TnSeq (neither essential nor dispensable can be inferred).
TA sites (Himar1) 35 in the ORF — 31 in the essential state, 0 growth-defect, 4 non-essential, 0 growth-advantage. Saturation 0.114, mean read count 121.75. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
34 of these 35 sites are exclusively this ORF's; Measured, not hypothetical: 1 of this ORF's 35 TA sites lies inside Rv0205 (1 site), leaving 34 sites that are exclusively its own. A transposon insertion cannot be assigned to one reading frame rather than the other, so the essentiality call rests on those 34 exclusive sites.
Caveat`essential: true` here is the broad union (ES+ESD+GD) kept for backward compatibility; this gene is NOT strictly essential. Read n_sites_* before writing anything about essentiality.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Chemical-genetic target & druggability (PROSPECT) hypomorph tool strain validated drug target

This gene is part of the PROSPECT collection of TetON transcriptional-knockdown (hypomorph) strains of essential M. tuberculosis genes, built as a sensitised background for chemical-genetic mechanism-of-action deconvolution. Being in the panel means the gene is an essential / vulnerable target for which a validated knockdown tool strain exists.

Hypomorph strainmmpL3_tetOn_6.2 (TetON promoter 6)
Baseline knockdown fitness3.962 median doublings (across 6 screen pool(s)) — fewer doublings = stronger growth defect on knockdown
Used in target deconvolutionyes (informs phenotypic-cluster / MOA assignment)
Drug-target cross-referenceannotated mechanism-of-action target MmpL3: 8 reference compound(s) phenocopy its inhibition — chemically-validated druggable target

Panel membership reflects essentiality/vulnerability and the availability of a genetic tool, not a specific molecular function; it never changes the verdict here. Source: Bond AN et al., Nat Commun 2025;16:9673 (doi:10.1038/s41467-025-64662-x); PROSPECT chemical-genetic platform.

Mutant phenotypes (conditional Tn-seq, MtbTnDB)

Conditionlog2FCqEffect
Mutants exhibiting altered fitness in the absence of gene marP (other) -5.370.014 required

Conditional fitness of transposon-disruption mutants across 1 significant condition(s) (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Provenance note on a condition above. `marP_KO_vs_marP_WT` carries no source in MtbTnDB's own metadata (col_desc.tsv leaves paper_title/paper_URL empty). Traced by the `Rv0537c` companion project (2026-09-12): Weizhen Xu, PhD thesis, Weill Cornell Medicine, 2017, hdl:1813/64728 ("Genetic Screening In Mycobacterium Tuberculosis Utilizing Transposon Insertion Sequencing"), whose abstract describes a TnSeq genetic-interaction screen naming marP. Never published as a peer-reviewed article.

Proteomics (mass spectrometry) detected

MS detectiondetected in 15 of 16 independent MS datasets
Integrated abundance256.0 ppm · rank 722/3519 (79.5th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox)

Predictionpredicted membrane protein (12 TM helixes)
DeepTMHMM classTM
TM helices (DeepTMHMM)12

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length944 aa
Molecular weight100.9 kDa
Theoretical pI9.48
GRAVY0.237 (hydrophobic)
Aliphatic index102.4
Aromaticity0.071
Instability index42.6 (unstable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
MMPLPF03176.22 4.4e-3847–340 MMPL family

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 7nvh (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 1 solved

PDBMethodResolutionCoverage
7nvh Electron Microscopy 3.0 Å 80%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (1 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 79.3

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
7nvh-assembly1_A 1.00 1.00 0.76 1.00 95% 80% / 100% 8.9e-95 sig 7nvh-assembly1_A Cryo-EM structure of the mycolic acid transporter MmpL3 from M. tuberculosis
7n6b-assembly1_A 1.00 0.98 0.79 0.98 71% 80% / 100% 5.2e-86 sig 7n6b-assembly1_A Structure of MmpL3 reconstituted into lipid nanodisc in the TMM bound state
6n40-assembly1_A 1.00 0.98 0.76 0.98 70% 79% / 100% 1.1e-80 sig 6n40-assembly1_A Crystal structure of MmpL3 from Mycobacterium smegmatis
7k7m-assembly1_A 1.00 0.96 0.77 0.96 72% 80% / 100% 1.5e-81 sig 7k7m-assembly1_A Crystal Structure of a membrane protein
8qkk-assembly1_A 1.00 0.95 0.74 0.95 71% 78% / 100% 3.3e-80 sig 8qkk-assembly1_A Cryo-EM structure of MmpL3 from Mycobacterium smegmatis reconstituted into peptidiscs

Foldseek search of the AlphaFold DB model (mean pLDDT 79.3, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon)

Upstream (5' on genome)Rv0205 (+ strand, -4 bp gap)
Downstream (3' on genome)Rv0207c (- strand, 65 bp gap)

Neighbours from the H37Rv annotation (- strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 3: mmpL3 · Rv0207c · Rv0208c — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT0216) exponential phase: operon of 3, Rv0206c · Rv0207c · Rv0208c (coverage 76.8)
stationary phase: operon of 3, Rv0206c · Rv0207c · Rv0208c (coverage 34.15) — disagrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: Rv0207c (hypothetical protein), high confidence (score 850, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 41 partners at medium confidence (8 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 41 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv0207c hypothetical protein 874 850 ctx neighborhood:798
Rv0208c trmB tRNA (guanine-N(7)-)-methyltransferase 862 837 ctx neighborhood:798
Rv0210 hypothetical protein 722 722 ctx neighborhood:721
Rv3909 dark hypothetical protein 722 666 ctx cooccurence:663
Rv3835 hypothetical protein 658 658 ctx cooccurence:653
Rv2739c transferase 640 640 ctx cooccurence:638
Rv2843 hypothetical protein 588 588 ctx cooccurence:588
Rv0007 membrane protein 564 551 ctx cooccurence:464
Rv1024 membrane protein 507 507 ctx cooccurence:501
Rv0209 hypothetical protein 487 487 ctx neighborhood:485
Rv3755c hypothetical protein 448 448 ctx cooccurence:440
Rv0444c rskA anti-sigma-K factor RskA 437 438 ctx cooccurence:433
Rv3668c protease 430 431 ctx cooccurence:429
Rv3494c mce4F Mce family protein Mce4 411 412 ctx cooccurence:405
Rv3682 ponA2 bifunctional penicillin-insensitive transglycosylase/penicillin-sensitive transpeptidase 421 387

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: transmembrane transport protein MmpL3
  • MTBC0 PGAP product: trehalose monomycolate RND transporter MmpL3
  • Pfam (hmmscan --cut_ga): MMPL PF03176.22 (E=4e-38)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_214720.1)
  • Domains: Pfam-A via hmmscan --cut_ga — MMPL (PF03176.22)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG2409
  • Curated reference: UniProt P9WJV5 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 79.3)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 41 functional partner(s); context anchor Rv0207c
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_000220|Rv0206c|mmpL3
MFAWWGRTVYRYRFIVIGVMVALCLGGGVFGLSLGKHVTQSGFYDDGSQSVQASVLGDQVYGRDRSGHIVAIFQAPAGKTVDDPAWSKKVVDELNRFQQDHPDQVLGWAGYLRASQATGMATADKKYTFVSIPLKGDDDDTILNNYKAIAPDLQRLDGGTVKLAGLQPVAEALTGTIATDQRRMEVLALPLVAVVLFFVFGGVIAAGLPVMVGGLCIAGALGIMRFLAIFGPVHYFAQPVVSLIGLGIAIDYGLFIVSRFREEIAEGYDTETAVRRTVITAGRTVTFSAVLIVASAIGLLLFPQGFLKSLTYATIASVMLSAILSITVLPACLGILGKHVDALGVRTLFRVPFLANWKISAAYLNWLADRLQRTKTREEVEAGFWGKLVNRVMKRPVLFAAPIVIIMILLIIPVGKLSLGGISEKYLPPTNSVRQAQEEFDKLFPGYRTNPLTLVIQTSNHQPVTDAQIADIRSKAMAIGGFIEPDNDPANMWQERAYAVGASKDPSVRVLQNGLINPADASKKLTELRAITPPKGITVLVGGTPALELDSIHGLFAKMPLMVVILLTTTIVLMFLAFGSVVLPIKATLMSALTLGSTMGILTWIFVDGHFSKWLNFTPTPLTAPVIGLIIALVFGLSTDYEVFLVSRMVEARERGMSTQEAIRIGTAATGRIITAAALIVAVVAGAFVFSDLVMMKYLAFGLMAALLLDATVVRMFLVPSVMKLLGDDCWWAPRWARRLQTRIGLGEIHLPDERKRPVSNGRPARPPVTAGLVAARAAGDPRPPHDPTHPLAESPRPARSSPASSPELTPALEATAAPAAPSGASTTRMQIGSSTEPPTTRLAAAGRSVQSPASTPPPTPTPPSAPSAGQTRAMPLAANRSTDAAGDPAEPTAALPIIRSDGDDSEAATEQLNARGTSDKTRQRRRGGGALSAQDLLRREGRL